hackint0sh/New-Dataset huggingface dataset:
Participants will attend 6 visits across a total duration of 11 weeks during the course of the study. conditions: Amputation conditions: Prosthesis User studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 16 type: ACTUAL name: 3d printed prosthetic socket measure: Prosthesis Evaluation Questionnaire measure: Socket Comfort Score sex: ALL minimumAge: 21 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tan Tock Seng Hospital city: Singapore zip: 308433 country: Singapore lat: 1.28967 lon: 103.85007 hasResults: False
nctId: NCT06361953 id: IR.SBMU.MSP.REC. 1401. 161 briefTitle: Comparing the Efficacy of Two Neurofeedback Protocols for Generalized Anxiety Disorder overallStatus: COMPLETED date: 2022-06-01 date: 2023-07-01 date: 2023-07-01 date: 2024-04-12 date: 2024-04-12 name: Shahid Beheshti University of Medical Sciences class: OTHER briefSummary: Generalized anxiety disorder (GAD) is one of the most prevalent mental disorders in adults, marked by excessive and uncontrollable worry about various events or activities. It is accompanied by symptoms such as restlessness, irritability, fatigue, difficulty concentrating, problems with sleep, and somatic symptoms.
In addition, a critical and up-to-date comparison of different treatments for GAD is crucial due to their high costs and unsatisfactory outcomes. EEG neurofeedback training has not reached the same level of evidence as more extensively validated non-pharmacological treatments, such as cognitive behavioral therapy.This study aimed to compare the efficacy of two protocols: one targeting alpha-theta amplitude increase and the other concentrating on SMR. conditions: Generalized Anxiety Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 40 type: ACTUAL name: EEG Neurofeedback measure: The Beck Anxiety Inventory measure: The Perceived Stress Questionnaire measure: Spielberger's state-trait anxiety test sex: ALL minimumAge: 20 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shahid Beheshti University of Medical Science city: Tehran zip: 4739-19395 country: Iran, Islamic Republic of lat: 35.69439 lon: 51.42151 hasResults: False
nctId: NCT06361940 id: IIT-CHAUDHARY-ENDOCRINE2-OPP briefTitle: Molecular Analyses to Identify Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer overallStatus: NOT_YET_RECRUITING date: 2024-08 date: 2028-12 date: 2029-12 date: 2024-04-12 date: 2024-04-15 name: Medical College of Wisconsin class: OTHER briefSummary: This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks). conditions: Breast Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 100 type: ESTIMATED name: Aromatase inhibitors or tamoxifen measure: Change from baseline in the number of subjects with increased HER-1 receptor tyrosine kinases protein expression in tumors. measure: Change from baseline in the number of subjects with increased HER-2 receptor tyrosine kinases protein expression in tumors. measure: Change from baseline in the number of subjects with increased HER-3 receptor tyrosine kinases protein expression in tumors. measure: Change from baseline in the number of subjects with increased HER-4 receptor tyrosine kinases protein expression in tumors. sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Froedtert Hospital and the Medical College of Wisconsin city: Milwaukee state: Wisconsin zip: 53226 country: United States name: Lubna N Chaudhary, MD role: CONTACT email: lchaudhary@mcw.edu lat: 43.0389 lon: -87.90647 hasResults: False
nctId: NCT06361927 id: SSGJ-707-NSCLC-II-01 briefTitle: A Phase II Study of SSGJ-707 Monotherapy in First-line PD-L1 Positive Advanced NSCLC Patients overallStatus: RECRUITING date: 2024-05 date: 2025-06 date: 2025-07 date: 2024-04-12 date: 2024-04-12 name: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. class: INDUSTRY briefSummary: This study includes two cohorts, cohort A is for non-squamous NSCLC and cohort B is for squamous NSCLC. conditions: NSCLC studyType: INTERVENTIONAL phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 120 type: ESTIMATED name: SSGJ-707 measure: ORR measure: Safety and tolerability sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: The Hunan Cancer Hospital status: RECRUITING city: Changsha state: Hunan country: China name: Lin Wu, MD,Ph.D role: CONTACT phone: 0731-89762302 email: wulin-calf@vip.163.com lat: 28.19874 lon: 112.97087 hasResults: False
nctId: NCT06361914 id: 2314393 briefTitle: Digital CBT-I for Patients With Chronic Pain and Insomnia acronym: Back2Sleep overallStatus: RECRUITING date: 2024-04-12 date: 2026-03-01 date: 2026-09-01 date: 2024-04-12 date: 2024-04-18 name: Odense University Hospital class: OTHER name: Aarhus University Hospital name: University of Southern Denmark name: University of Aarhus name: Odense Patient Data Explorative Network name: T&W Engineering A/S briefSummary: Chronic pain constitutes an increasing health and social burden. More than 50% of patients with chronic pain report insomnia, and patients with comorbid insomnia often report stronger and widespread pain, compared to those who are sleeping well. Sleep disturbances are often considered a consequence to chronic pain. This means that insomnia is often overlooked or ineffectively managed with hypnotics or advice on sleep hygiene. Therefore, efficacious, easily accessible, and safe alternatives to the current pharmacological treatments for patients with chronic pain and insomnia are needed. Cognitive behavioral therapy for insomnia (CBT-I) is a cost-effective and safe treatment for insomnia and is recommended as first-line treatment. While highly efficacious, the challenge is to deliver CBT-I to those in need. The main barriers of face-to-face delivered CBT-I are availability of trained therapists, costs, as well as physical and geographical constraints.
nctId: NCT06361901 id: 2023GR0452 briefTitle: Comparison of Therapeutic Effect Between Speech Rehabilitation Program and Speech Therapy in Stroke Patients With Aphasia overallStatus: RECRUITING date: 2023-11-17 date: 2024-12 date: 2024-12 date: 2024-04-12 date: 2024-04-12 name: Korea University Guro Hospital class: OTHER briefSummary: Our study will provide precise and intensive speech rehabilitation treatment program to patients with speech disorders after stroke, and compare clinical evaluations with the conventional speech therapy patient group.
* Cerebral blood flow changes with near-infrared spectroscopy conditions: Stroke conditions: Aphasia conditions: Speech Therapy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Zenicog;language rehabilitation program name: Conventional language rehabilitation measure: Aphasic quatient measure: Change of cerebral blood flow sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Department of Rehabilitation Medicine, Korea University Guro Hospital status: RECRUITING city: Seoul zip: 08308 country: Korea, Republic of name: Seung Nam Yang, MD, PhD role: CONTACT phone: 82-2-2626-1500 email: snamyang@korea.ac.kr lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06361888 id: 2023-012-00CH1 briefTitle: A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer overallStatus: NOT_YET_RECRUITING date: 2024-05-31 date: 2027-08-31 date: 2027-08-31 date: 2024-04-12 date: 2024-04-12 name: Hutchmed class: INDUSTRY briefSummary: To evaluate the efficacy of Surufatnib combined withcamrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer conditions: Metastatic Pancreatic Cancer studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 482 type: ESTIMATED name: Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine name: Nab-paclitaxel Plus Gemcitabine name: Surufatinib with Nab-paclitaxel, and Gemcitabine measure: Overall Survival (OS) measure: Progression-free Survival (PFS) (RECIST1.1) measure: Objective response rate (ORR)(RECIST1.1) measure: Duration of response (DoR)(RECIST1.1) measure: Disease control rate (DCR)(RECIST1.1) measure: Cancer Quality of Life Questionnaire - Core 30 (EORTC QLQ-C30) measure: Cancer Quality of Life Questionnaire - PAN26(EORTC QLQ-PAN26) sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Nanjing Tianyinshan Hospital city: Nanjing state: Jiang Su zip: 210000 country: China name: Shukui Qin, Prof. role: CONTACT lat: 32.06167 lon: 118.77778 facility: Tianjin Cancer Hospital city: Tianjin state: Tianjin zip: 300000 country: China name: Jihui Hao, Prof. role: CONTACT lat: 39.14222 lon: 117.17667 hasResults: False
nctId: NCT06361862 id: WARD - Overtreatment briefTitle: Does Continuous Vital Sign Monitoring Increase Investigations and Interventions in Complication-free Patients? acronym: WARD-OT overallStatus: RECRUITING date: 2024-01-01 date: 2025-03-01 date: 2025-04-01 date: 2024-04-12 date: 2024-04-12 name: Rigshospitalet, Denmark class: OTHER name: Bispebjerg Hospital briefSummary: This aim of this study is to investigate whether active alerts during CVSM result in an increased number of diagnostic tests and treatments in complication free patients, hypothesizing that more interventions are performed in the CVSM-group than standard of care (EWS) group. conditions: Cancer conditions: Chronic Obstructive Pulmonary Disease conditions: Surgery-Complications studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 700 type: ESTIMATED name: Active alarms from WARD software measure: Frequency of patients having at least one of the following tests/treatments: measure: The frequency of individual treatments and diagnostics: sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Eske Kvanner Aasvang status: RECRUITING city: Copenhagen zip: 2100 country: Denmark name: Eske K Aasvang, M.D., DMSci role: CONTACT phone: +4526232076 email: eske.kvanner.aasvang.01@regionh.dk lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06361849 id: 55013 briefTitle: TauTona Pneumoperitoneum Assist Device (TPAD) acronym: TPAD overallStatus: ENROLLING_BY_INVITATION date: 2024-01-01 date: 2024-12-31 date: 2025-06-01 date: 2024-04-12 date: 2024-04-24 name: Stanford University class: OTHER name: TauTona Group briefSummary: The purpose of this study is to assess the safety and ease of use of a trocar placement access device (TPAD) to assist with obtaining peritoneal access with a Veress needle, and for placing a primary trocar, during laparoscopic surgery. conditions: Laparoscopic Surgery studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: SINGLE_GROUP primaryPurpose: DEVICE_FEASIBILITY masking: NONE count: 10 type: ESTIMATED name: Trocar Placement Assist Device (TPAD) measure: Surgeon satisfaction survey measure: Time required to obtain peritoneal access and place primary trocar during laparoscopic surgery measure: Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0 sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Stanford Hospital & Clinics city: Palo Alto state: California zip: 94305 country: United States lat: 37.44188 lon: -122.14302 hasResults: False
nctId: NCT06361836 id: SBT777101-02 briefTitle: Study of Single Doses of SBT777101 in Subjects With Hidradenitis Suppurativa overallStatus: RECRUITING date: 2024-05 date: 2026-06 date: 2026-06 date: 2024-04-12 date: 2024-04-12 name: Sonoma Biotherapeutics, Inc. class: INDUSTRY briefSummary: This study will test the safety and effects of SBT777101 when given as a single dose to subjects with hidradenitis suppurativa. Increasing dose levels will be given after the safety at lower dose levels is shown. conditions: Hidradenitis Suppurativa studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: Sequential escalating dose cohorts primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: SBT777101 measure: Incidence, nature, and severity of adverse events [Safety and Tolerability] measure: Incidence and nature of Dose Limiting Toxicities [DLTs] sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Brigham and Women's Hospital status: RECRUITING city: Boston state: Massachusetts zip: 02115 country: United States name: Oliva Gabriel role: CONTACT phone: 617-525-8250 email: ogabriel@bwh.harvard.edu lat: 42.35843 lon: -71.05977 hasResults: False
nctId: NCT06361823 id: IIH-Semaglutide briefTitle: Exploratory Study on the Efficacy and Safety of Semaglutide for Idiopathic Intracranial Hypertension Treatment overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-12-01 date: 2025-01-01 date: 2024-04-12 date: 2024-04-12 name: Capital Medical University class: OTHER briefSummary: This study aims to investigate the safety and efficacy of semaglutide in patients with Idiopathic intracranial hypertension. conditions: Idiopathic Intracranial Hypertension studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The researchers are tasked with adhering to the protocol requirements when selecting participants, and consistently enrolling eligible patients who are then randomly assigned to either the experimental or control group in a 1:1 ratio. The randomization process is overseen by expert statisticians and executed by specialized clinical researchers in an independent manner. primaryPurpose: TREATMENT masking: NONE count: 74 type: ESTIMATED name: Semaglutide name: Low calorie diet measure: Intracranial pressure measure: Adverse reactions measure: Headache severity measure: Degree of papilledema measure: Perimetric mean deviation measure: Optic nerve sheath diameter measure: Body mass index sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06361810 id: IRB00430008 briefTitle: PSMA Therapy and Immunotherapy in Kidney Cancer overallStatus: NOT_YET_RECRUITING date: 2024-07 date: 2030-07 date: 2031-07 date: 2024-04-12 date: 2024-04-12 name: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins class: OTHER name: Merck Sharp & Dohme LLC name: Lantheus Medical Imaging briefSummary: This is a multi-center, single arm open label phase 1b/2 study of pembrolizumab in combination with 177Lu-PNT2002 (also known as 177Lu-PSMA I\&T) radiopharmaceutical therapy in patients with metastatic clear cell renal cell carcinoma (RCC) who have progressed after prior treatment with anti-programmed cell death protein 1 (PD1) or PD-L1 immune-checkpoint inhibitors (ICIs). The study comprises 2 phases: an open-label Phase 1b dose escalation portion followed by a Phase 2 dose expansion portion. Investigators hypothesize that pembrolizumab in combination with 177Lu-PNT2002 in in patients with metastatic clear cell RCC at a biologically active dose will result in tolerable safety profile and it will lead to improved radiological objective responses in patients who have progressed after prior treatment with standard anti-PD1 or anti- Programmed Cell Death Ligand 1 (PDL1) immune-checkpoint inhibitor containing regimen when compared to historic controls. Patients in both phases will have prostate-specific membrane antigen (PSMA), positron emission tomography (PET) imaging with the radiotracer (F-18)-DCFPyl, to help detect any spread of the cancer. conditions: Metastatic Renal Cell Carcinoma conditions: Metastatic Clear Cell Renal Cell Carcinoma studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 37 type: ESTIMATED name: Pembrolizumab name: 177Lu-PNT2002 name: (F-18)-DCFPyL measure: Safety assessed by the incidence of dose limiting toxicities. measure: Objective response rate by RECIST 1.1 criteria measure: Progression free survival measure: Safety as assessed by number of participants experiencing adverse events measure: Disease control rates measure: Duration of response to study therapy measure: Overall survival rate sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06361797 id: IRB00415412 briefTitle: Varying Bone Marrow-Derived Mesenchymal Stem Cells Concentrations' Impact on Rotator Cuff Repair Outcomes overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2027-10 date: 2024-04-12 date: 2024-04-12 name: Johns Hopkins University class: OTHER name: ON Foundation briefSummary: Randomized controlled trial comparing benefits of varying amounts of proximal humerus-derived bone marrow aspirate and bone marrow concentrate in rotator cuff repair. conditions: Rotator Cuff Tears studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: This study is designed as a parallel group 1:1:1 randomized controlled trial. primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: Patients and research assistants collecting data will be unaware of assigned treatment until study completion. whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 150 type: ESTIMATED name: Rotator cuff repair augmented with whole bone marrow name: Rotator cuff repair augmented with concentrated bone marrow measure: Number of Rotator cuff re-tears as assessed by magnetic resonance imaging measure: American Shoulder and Elbow Surgeons Score measure: Visual Analogue Pain Score measure: Subjective Shoulder Value score measure: Comprehensive Shoulder Assessment measure: Revision surgery rate measure: Rate of oral and/or intra-articular corticosteroid required sex: ALL minimumAge: 20 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins Howard County General Hospital city: Columbia state: Maryland zip: 21230 country: United States name: Study Director role: CONTACT name: Principal Investigator role: CONTACT lat: 39.24038 lon: -76.83942 facility: Johns Hopkins Medicine - Green Spring Station city: Lutherville state: Maryland zip: 21093 country: United States name: Matthew J Best, MD role: CONTACT phone: 443-997-2663 email: mbest8@jh.edu name: Uma Srikumaran, MD, MBA, MPH role: CONTACT phone: 410-546-1550 email: us@jhmi.edu lat: 39.42122 lon: -76.62608 hasResults: False
nctId: NCT06361784 id: INT216-23 id: MFAG27480 type: OTHER_GRANT domain: AIRC Foundation for Cancer Research in Italy briefTitle: Improving the Success Rate for Thoracic Radiotherapy Through Specific Cardiac Substructure Dosimetry: Location Matters. (LOCATION MATTERS) acronym: LM overallStatus: RECRUITING date: 2024-03-29 date: 2029-03-29 date: 2029-03-29 date: 2024-04-12 date: 2024-04-15 name: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano class: OTHER name: Politecnico di Milano briefSummary: The prospective study LOCATION MATTERS aims to investigate the radiation-induced damage to the heart and the cardiovascular system in patients treated with thoracic radiotherapy. Patients enrolled in the study will complete a set of extensive measures at the baseline, end of RT, and 9 months after treatment. Ultrasound exams, CT scans, pulmonary tests and wearable devices will assess functional and morphological parameters and the association with their variation and the dose delivered to the heart substructures and to the normal lung. conditions: Locally Advanced Lung Non-Small Cell Carcinoma studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 150 type: ESTIMATED measure: Variation in eco-cardio and eco-vascular parameters after thoracic radiotherapy measure: Major adverse cardiac events post-RT measure: Increase in cardiac calcification after RT measure: Longitudinal variation of cardiopulmonary functional parameters measure: Texture variation in the heart substructures sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione IRCCS Istituto Nazionale dei Tumori status: RECRUITING city: Milan zip: 20133 country: Italy name: Alessandro Cicchetti, PhD role: CONTACT phone: 0223903858 email: alessandro.cicchetti@istitutotumori.mi.it name: Chiara Casati role: CONTACT email: chiara.casati@istitutotumori.mi.it name: Alessandro Cicchetti, PhD role: PRINCIPAL_INVESTIGATOR lat: 45.46427 lon: 9.18951 hasResults: False
nctId: NCT06361771 id: 29BRC24.0079 - PRICELESS briefTitle: Evaluation of Invisible Preparation Behaviors of Middle and High School Students in Sports Facilities (PRICELESS) acronym: PRICELESS overallStatus: RECRUITING date: 2024-01-08 date: 2024-12-20 date: 2024-12-20 date: 2024-04-12 date: 2024-04-18 name: University Hospital, Brest class: OTHER briefSummary: The investigators define the Invisible Preparation (IP) as the set of health behaviors that young athletes implement, on their own, to optimize their health and performances. This includes sleep, nutrition and hydration, physical well-being (injuries prevention) and mental well-being. If some studies have reported a lack of compliance in young athletes regarding sleep and hydration recommendations, the literature is poor in this field.
Under the direction of the Brest University Hospital, PRICELESS (Invisible Preparation of Middle and High School Students in Sports Institutions) study will try, based on their answers, to estimate the proportion of young athletes who declare adopting the health behaviors recommended in the IP. conditions: Sports Injury conditions: Prevention conditions: Training conditions: Hydration conditions: Nutrition conditions: Sleep conditions: Mental Health conditions: Physical Well-Being studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 1500 type: ESTIMATED measure: The proportion of teenagers who declare adopting the health behaviors recommended in the four areas of the Invisible Preparation. measure: The proportion of girls who declare adopting these behaviors, compared to the proportion in boys. measure: The proportion of Middle School students who declare adopting these behaviors, compared to the proportion in High School students. measure: The proportion of young athletes practicing an intensive sporting activity (10 hours or more per week), compared to the proportion in young athletes practicing a non-intensive sporting activity (less than 10 hours per week). measure: The proportion of young athletes with disabilities who declare adopting these behaviors, compared to the proportion in young athletes without disabilities. sex: ALL minimumAge: 9 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT facility: Chu Brest status: RECRUITING city: Brest zip: 29609 country: France name: Marie-Agnès GIROUX-METGES, PhD role: CONTACT phone: 0298347366 phoneExt: +33 email: marie-agnes.metges@chu-brest.fr name: Florent GUIMARD, Resident role: CONTACT phone: 02 98 33 53 40 phoneExt: +33 email: florent.guimard@chu-brest.fr lat: 48.3903 lon: -4.48628 hasResults: False